JP Morgan Chase’s Genetic Technologies Ltd. GENE Stock Holding History

JP Morgan Chase’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-18	Closed	–	–	6440
2020 Q4	$0	Buy	+18	New	+$297	﹤0.01%	6014

Other funds holding GENE

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

EGM

Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

JP Morgan Chase's GENE Position: Q1 2021 in Review

JP Morgan Chase sold out of Genetic Technologies Ltd. (GENE) in Q1 2021, closing a stake of 18 shares.

JP Morgan Chase first reported a position in GENE in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 17 funds tracked by Wall St. Rank hold GENE as of Q1 2021.

JP Morgan Chase reported no remaining Genetic Technologies Ltd. position as of Q1 2021 after selling out during the quarter.
JP Morgan Chase sold 18 Genetic Technologies Ltd. shares in Q1 2021.
JP Morgan Chase first reported a position in Genetic Technologies Ltd. in Q4 2020 and held it in 1 quarter.
JP Morgan Chase's Genetic Technologies Ltd. position peaked at $0 in Q4 2020.
17 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q1 2021.

Based on JP Morgan Chase's 13F filing for Q1 2021, filed 12 May 2021.